Physician profile
Ion Botnaru
NPI 1174796080
$3,243.51
in general payments reported to CMS, 2019-2025
32 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.93 · 2021: $605 · 2022: $765 · 2023: $692 · 2024: $509 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810 · Travel and Lodging: $23.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.83 |
| Travel and Lodging | $23.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $411.18 | 2021-2025 | Lifevest |
| Abbott Laboratories | $314.39 | 2019-2025 | Perclose Prostyle, Diamondback Coronary, Diamondback Peripheral |
| Abiomed | $274.94 | 2022-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $229.34 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $215.11 | 2021-2023 | Farxiga |
| Cardiovascular Systems INC. | $171.71 | 2022-2023 | |
| Medtronic, INC. | $154.60 | 2021-2023 | Linq II |
| United Therapeutics Corporation | $138.44 | 2021 | |
| Boston Scientific Corporation | $134.02 | 2021-2025 | Cds - Mct/Cem Monitoring, Accolade Sr, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.75 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $126.30 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $110.78 | 2024 | Onpattro |
| Amgen INC. | $109.43 | 2021-2024 | Repatha |
| Philips North America LLC | $96.21 | 2023-2025 | (Ck4) Mcot, Mcot |
| Pfizer INC. | $78.57 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $78.16 | 2022-2023 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $54.97 | 2025 | |
| Stryker Corporation | $43.15 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Clottriever Bold Catheter |
| Kestra Medical Technology Services, INC. | $36.85 | 2024-2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $35.99 | 2023 | Inpefa |
| Kerecis Limited | $33.89 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Atricure, INC. | $32.69 | 2023 | |
| Inari Medical, INC. | $32.63 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kiniksa Pharmaceuticals International, Plc | $31.24 | 2024 | Arcalyst |
| Penumbra, INC. | $30.28 | 2021-2022 | |
| Irhythm Technologies, INC. | $25.87 | 2023 | Zio Xt Patch |
| Shockwave Medical, INC | $24.36 | 2022 | |
| Amarin Pharma, INC. | $20.48 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $18.53 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $16.59 | 2021 | |
| Novo Nordisk INC | $15.19 | 2022 | |
| Teleflex LLC | $14.87 | 2025 | Trapliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ion Botnaru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.